S&P 500
(1.02%) 5 099.96 points
Dow Jones
(0.40%) 38 240 points
Nasdaq
(2.03%) 15 928 points
Oil
(-0.94%) $83.06
Gas
(-1.16%) $1.619
Gold
(-0.27%) $2 340.80
Silver
(-1.00%) $27.26
Platinum
(0.53%) $927.00
USD/EUR
(-0.17%) $0.933
USD/NOK
(-0.16%) $11.01
USD/GBP
(-0.24%) $0.798
USD/RUB
(0.00%) $92.17

リアルタイムの更新: Epigenomics AG [EPGNY]

取引所: OTC セクター: Healthcare 産業: Diagnostics & Research
最終更新日時22 9月 2022 @ 03:34

0.00% $ 2.39

Live Chart Being Loaded With Signals

Commentary (22 9月 2022 @ 03:34):

Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer in the United States, Europe, and China...

Stats
本日の出来高 212.00
平均出来高 9.00
時価総額 0.00
Last Dividend $0.0297 ( 2021-09-16 )
Next Dividend $0 ( N/A )
P/E -1.604
ATR14 $0 (0.00%)

Epigenomics AG 相関

10 最も正の相関
10 最も負の相関

知っていましたか?

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Epigenomics AG 財務諸表

Annual 2021
収益: $6.20M
総利益: $6.07M (97.81 %)
EPS: $-0.271
FY 2021
収益: $6.20M
総利益: $6.07M (97.81 %)
EPS: $-0.271
FY 2020
収益: $842 000
総利益: $697 000 (82.78 %)
EPS: $-2.48
FY 2019
収益: $1.13M
総利益: $872 000 (77.51 %)
EPS: $-4.48

Financial Reports:

No articles found.

Epigenomics AG Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)

Epigenomics AG Dividend Information - No Dividend Player

Dividend Sustainability Score: 0.458 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future
Information
First Dividend $0.833 2018-10-31
Last Dividend $0.0297 2021-09-16
Next Dividend $0 N/A
Payout Date 0000-00-00
Next Payout Date N/A
# dividends 5 --
Total Paid Out $2.72 --
Avg. Dividend % Per Year 0.00% --
Score 0.55 --
Div. Sustainability Score 0.458
Div.Growth Potential Score 0
Div. Directional Score 0 --
Next Divdend (Est)
(2024-09-23)
$0 Estimate 0.00 %
Dividend Stability
0.05 Very Bad
Dividend Score
0.55
Pay Frequency
Annually
Yearly Payout
Year Amount Yield

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for OTC

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
PLDGP Ex Dividend Knight 2023-09-15 Quarterly 0 0.00%
EDPFY Ex Dividend Junior 2023-05-01 Annually 0 0.00%
UEPEM Ex Dividend Knight 2023-07-20 Quarterly 0 0.00%
KBCSY Ex Dividend Junior 2023-05-09 Annually 0 0.00%
BYDDF Ex Dividend Junior 2023-06-13 Sporadic 0 0.00%
RWWI Ex Dividend Knight 2023-06-02 Quarterly 0 0.00%
FINN Ex Dividend Knight 2023-08-07 Bi-Monthly 0 0.00%
WJRYF Ex Dividend Knight 2023-09-28 Annually 0 0.00%
MCBK Ex Dividend Junior 2023-05-02 Annually 0 0.00%
CMSQY Ex Dividend Knight 2023-08-22 Annually 0 0.00%

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM-0.3911.500-7.83-10.00[0 - 0.5]
returnOnAssetsTTM-0.09841.200-3.28-3.94[0 - 0.3]
returnOnEquityTTM-0.1871.500-3.19-4.78[0.1 - 1]
payoutRatioTTM0-1.00000[0 - 1]
currentRatioTTM11.060.80010.008.00[1 - 3]
quickRatioTTM10.720.80010.008.00[0.8 - 2.5]
cashRatioTTM10.721.50010.0010.00[0.2 - 2]
debtRatioTTM0.0187-1.5009.69-10.00[0 - 0.6]
interestCoverageTTM-45.351.000-10.00-10.00[3 - 30]
operatingCashFlowPerShareTTM-0.4632.00-0.154-0.309[0 - 30]
freeCashFlowPerShareTTM-0.4672.00-0.233-0.467[0 - 20]
debtEquityRatioTTM0.0208-1.5009.92-10.00[0 - 2.5]
grossProfitMarginTTM0.9781.00010.0010.00[0.2 - 0.8]
operatingProfitMarginTTM-0.3801.000-9.60-9.60[0.1 - 0.6]
cashFlowToDebtRatioTTM-9.031.000-10.00-10.00[0.2 - 2]
assetTurnoverTTM0.2520.800-1.657-1.325[0.5 - 2]
Total Score0.458

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM-8.251.000-0.9340[1 - 100]
returnOnEquityTTM-0.1872.50-2.05-4.78[0.1 - 1.5]
freeCashFlowPerShareTTM-0.4672.00-0.156-0.467[0 - 30]
dividendYielPercentageTTM01.50000[0 - 0.4]
operatingCashFlowPerShareTTM-0.4632.00-0.154-0.309[0 - 30]
payoutRatioTTM01.50000[0 - 1]
pegRatioTTM-0.4631.500-6.420[0.5 - 2]
operatingCashFlowSalesRatioTTM-0.6691.000-10.000[0.1 - 0.5]
Total Score-2.63

Epigenomics AG

Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer in the United States, Europe, and China. The company's products also include hepatocellular carcinoma blood test; Epi proColon, a liquid biopsy test for detection of colorectal cancer; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA. Its research and development activities identify suitable biomarkers in human tissue and developing and patenting the corresponding in vitro diagnostic blood tests. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany.

について ライブシグナル

このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。